562 results on '"Trojan, Lutz"'
Search Results
52. Insulin‐like growth factor 2 expression in prostate cancer is regulated by promoter‐specific methylation
53. T1 Mapping of the Prostate Using Single-Shot T1FLASH: A Clinical Feasibility Study to Optimize Prostate Cancer Assessment.
54. Prospective evaluation of an intraoperative urodynamic stress test predicting urinary incontinence after robot-assisted laparoscopic radical prostatectomy.
55. The lymphatic system in clinically localized urothelial carcinoma of the bladder: Morphologic characteristics and predictive value
56. Gender-specific differences in cancer-specific survival after radical cystectomy for patients with urothelial carcinoma of the urinary bladder in pathologic tumor stage T4a
57. Lymph vessel density in seminomatous testicular cancer assessed with the specific lymphatic endothelium cell markers D2-40 and LYVE-1: Correlation with pathologic parameters and clinical outcome
58. Biphasic 68Ga-PSMA-HBED-CC-PET/CT in patients with recurrent and high-risk prostate carcinoma
59. Surgical Anatomy of the Prostate Sphincter Complex
60. Cognitive Ability as a Non-modifiable Risk Factor for Post-prostatectomy Urinary Incontinence: A Double-Blinded, Prospective, Single-Center Trial
61. Analysis of Sex Differences in Cancer-Specific Survival and Perioperative Mortality Following Radical Cystectomy: Results of a Large German Multicenter Study of Nearly 2500 Patients with Urothelial Carcinoma of the Bladder
62. External Validation of a Risk Model to Predict Recurrence-Free Survival After Radical Cystectomy in Patients With Pathological Tumor Stage T3N0 Urothelial Carcinoma of the Bladder
63. The prognostic impact of Claudin 6 in papillary renal cell carcinoma
64. cMET: a prognostic marker in papillary renal cell carcinoma?
65. Expression of Prostate-specific Membrane Antigen (PSMA) in Papillary Renal Cell Carcinoma - Overview and Report on a Large Multicenter Cohort
66. The Prognostic Impact of PD-L2 in Papillary Renal-Cell Carcinoma
67. Increased expression of CYP17A1 indicates an effective targeting of the androgen receptor axis in castration resistant prostate cancer (CRPC)
68. Impact of mpMRI targeted biopsy on intraoperative nerve‐sparing (NeuroSAFE) during robot‐assisted laparoscopic radical prostatectomy
69. See the Unseen: Mesorectal Lymph Node Metastases in Prostate Cancer
70. Einleitung Grundsätze der medikamentösen Tumortherapie, Schmerztherapie, komplementäre Medizin und Palliativtherapie
71. Urine from current smokers induces centrosome aberrations and spindle defects in vitro in nonmalignant human cell lines
72. Prognostic Factors of Papillary Renal Cell Carcinoma: Results From a Multi-Institutional Series After Pathological Review
73. CTLA4 promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma
74. Novel options for the treatment of castration-resistant prostate cancer
75. Modulating the Heat Sensitivity of Prostate Cancer Cell Lines In Vitro: A New Impact for Focal Therapies
76. Association Between the Number of Dissected Lymph Nodes During Pelvic Lymphadenectomy and Cancer-Specific Survival in Patients with Lymph Node–Negative Urothelial Carcinoma of the Bladder Undergoing Radical Cystectomy
77. Prognostic Implications of Lymphangiogenesis in Muscle-Invasive Transitional Cell Carcinoma of the Bladder
78. Lymphovascular Invasion and Pathologic Tumor Stage Are Significant Outcome Predictors for Patients With Upper Tract Urothelial Carcinoma
79. Clinical impact of intraoperative frozen sections during nerve-sparing radical prostatectomy
80. In vivo evaluation of intravesical paclitaxel and combined bcl-xL antisense oligodeoxynucleotide treatment for orthotopic urothelial carcinoma
81. An alternative continence tube for continent urinary reservoirs: evaluation of surgical technique, pressure and continence study in an ex-vivo model
82. Mesorectal Lymph Node Metastases as Index Lesion in 68Ga-PSMA-PET/CT Imaging for Recurrent Prostate Cancer
83. Toxicities of axitinib, sunitinib and temsirolimus: implications for progression-free and overall survival in metastatic renal cell cancer
84. Testosterone boosts for treatment of castration resistant prostate cancer: An experimental implementation of intermittent androgen deprivation
85. A pragmatic radiomics and machine learning approach
86. Complications in Percutaneous Nephrolithotomy
87. Optimizing chemotherapy for transitional cell carcinoma by application of bcl-2 and bcl-xL antisense oligodeoxynucleotides
88. Simple models improve the discrimination of prostate cancers from the peripheral gland by T1-weighted dynamic MRI
89. Micelle delivery of doxorubicin increases cytotoxicity to prostate carcinoma cells
90. The influence of oxalate on renal epithelial and interstitial cells
91. Impact of holmium:YAG and neodymium:YAG lasers on the efficacy of DNA delivery in transitional cell carcinoma
92. In vitro and ex vivo gene delivery into proximal tubular cells by means of laser energy—a potential approach for curing cystinuria?
93. Expression of pro-angiogenic growth factors VEGF, EGF and bFGF and their topographical relation to neovascularisation in prostate cancer
94. Radiomic Features and Machine Learning for the Discrimination of Renal Tumor Histological Subtypes: A Pragmatic Study Using Clinical-Routine Computed Tomography
95. Silent operating theatre optimisation system for positive impact on surgical staff-members' stress, exhaustion, activity and concentration in urological da Vinci surgeries
96. New insights into the influence of cigarette smoking on urothelial carcinogenesis: Smoking-induced gene expression in tumor-free urothelium might discriminate muscle-invasive from nonmuscle-invasive urothelial bladder cancer
97. Impact of mpMRI targeted biopsy on intraoperative nerve‐sparing (NeuroSAFE) during robot‐assisted laparoscopic radical prostatectomy.
98. IGF-II Serum Levels Increase Discrimination Between Benign Prostatic Hyperplasia and Prostate Cancer and Improve the Predictive Value of PSA in Clinical Staging
99. EXTERNAL VALIDATION OF DISEASE-FREE SURVIVAL AT 2 OR 3 YEARS AS A SURROGATE AND NEW PRIMARY ENDPOINT FOR PATIENTS UNDERGOING RADICAL CYSTECTOMY FOR MUSCLE INVASIVE UROTHELIAL CANCER OF THE BLADDER: 530
100. Neuroendocrine tumor cells in prostate cancer: Evaluation of the neurosecretory products serotonin, bombesin, and gastrin – impact on angiogenesis and clinical follow-up
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.